. 2023;24(9):3169–3182. doi: 10.31557/APJCP.2023.24.9.3169

Table 5.

Effect of Different Variables on Disease Free Survival (DFS) of AML Patients:

	Total No.		No. of Events			Cumulative survival at 1year (%)		Median survival time (months)		P value
Whole group	51		29			0.29		11.55
Gender
Female	19		14			NR		6.12		0.008
Male	32		15			0.419		15
Age (years)
≤40	31		21			0.081		8.03		0.048
>40	20		8			0.579		NR
TLC
≤100 x10⁹/L	38		21			0.309		10.99		0.762
>100 x10⁹/L	11		6			0.36		12.04
Hemoglobin
≤10 g/dl	46		26			0.28		10.99		*
>10 g/dl	3		1			0.667
Platelets
≤100x10⁹/L	39		22			0.276		8.03		0.527
>100 x10⁹/L	10		5			0.411		12.04
PB blasts%
≤ 50	13		8			0.186		7.24		0.862
> 50	38		21			0.319		12.04
BMA blast%
≤ 50	8		5			0.219		6.78		0.96
> 50	43		24			0.308		11.55
BMA cellularity
Hypercellular	44		25			0.273		10.99		*
Hypocellular	4		3					6.51
Normocellular	3		1			0.667
FAB classification
M1&M2	23		13			0.385		6.78		0.448
M4&M5	26		14			0.339		21.71
LNS
No	29		14			0.466		12.4		0.37
Yes	21		14			0.098		11.55
Organomegally
No	34		20			0.282		12.4		0.861
Yes	16		8			0.323		11.55
CD34
No	23		13			0.306		10.99		0.942
Yes	28		16			0.275		11.55
DR
No	11		6			0.305		11.55		0.799
Yes	40		23			0.291		10.99
CD7
No	40		21			0.335		12.04		0.579
Yes	11		8			0.17		10.99
NPM
Mutant	10		2			0.45		23.72		0.036
Wild	35		25			0.221		7.04
FLT3 ITD
Mutant	13		7					5.16		0.173
Wild	38		22			0.323		12.4
ITD Ratio
≤ 0.525	5		3			NA		12.04		0.171
>0.525	5		2			NA		5.16
TKD
Mutant	3		2			0.333		6.78		*
Wild	47		26			0.285		11.55
DNMTA
Mutant	5		4			0.2		6.51		0.384
Wild	45		24			0.307		12.4
Combined FLT3&NPM with ITD ratio
Favourable (a)		9		2	0.889		23.72		0.011
Unfavorable (b)		3		2	NA		2.47
Intermediate (b)		33		23	0.391		7.24
IDH1&IDH2
Either IDH1 and or IDH2 mutant		3		1	0.667				*
Both wild		48		28	0.262		10.99
TET2
Mutant		31		20	0.323		7.04		0.079
Wild		20		9	0.71		21.71